BGB (ALUNBRIG tablets) is an orally available ALK inhibitor that demonstrated ability to overcome crizotinib resistance mutations.12,13 On April 28, 2017, BGB was approved by the US FDA for the treatment of patients with metastatic ALK-positive NSCLC that have progressed on or are intolerant to crizotinib. Here, ALK is linked to non-small cell lung carcinoma.